New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome
9:58
אין תגובות
Kristina A. Cole and John M. Maris
Clin Cancer Res; 18(9); 2423–8. 2012 AACR.
DOI: 10.1158/1078-0432.CCR-11-1409 Published May 2012
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
17:11
סגור לתגובות על Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
The objective of this guideline is to provide healthcare professionals with clear, up-to-date, and practical guidance on the management
How I treat polycythemia vera
12:29
סגור לתגובות על How I treat polycythemia vera
Polycythemia vera (PV) is a clonal disorder characterized by unwarranted production
How I treat pediatric acute myeloid leukemia
11:16
סגור לתגובות על How I treat pediatric acute myeloid leukemia
Acute myeloid leukemia is a heterogeneous disease that accounts for approximately
RMS 2005 – a protocol for non metastatic rhabdomyosarcoma
16:32
אין תגובות
EpSSG RMS 2005 protocol
Version 1.3
Diagnosis and management of acute graft-versus-host disease
15:18
סגור לתגובות על Diagnosis and management of acute graft-versus-host disease
Dignan, F. L., et al., Br J Haematol, 158: 30-45.
How I treat acquired aplastic anemia
11:27
סגור לתגובות על How I treat acquired aplastic anemia
Survival in severe aplastic anemia (SAA) has markedly improved in the
MODIFICATION OF ELIGIBILITY CRITERIA FOR STEM CELL TRANSPLANTATION FOR THE AMENDED ESPHALL PROTOCOL
14:16
אין תגובות
The amended version of the EsPhALL protocol is being applied since 2010. At that time, no evidence could suggest
